Theriva Biologics
TOVX
27 hedge funds and large institutions have $5.8M invested in Theriva Biologics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 4 closing their positions.
722% more capital invested
Capital invested by funds: $705K → $5.8M (+$5.09M)
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
59% more funds holding
Funds holding: 17 → 27 (+10)
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.83M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.56M |
| 3 |
MP
MSD Partners
New York
|
+$759K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$666K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$456K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$474K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$28K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$6K | -63 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$11.7K | -59 | Closed |
|
28
Barclays
London,
United Kingdom
| – | +$395 | +2 | New |
|
|
FWM
29
Focused Wealth Management
Newburgh,
New York
| – | +$395 | +2 | New |
|
|
PP
30
PrairieView Partners
St. Paul,
Minnesota
| – | +$395 | +2 | New |
|
TOVX Hedge Fund Activity: Q1 2021 in Review
27 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2021, worth a combined $5.8M — up 722% from $705K a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TOVX positions and 4 closed out — a net gain of 10 holders — while 8 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, adding an estimated $1.83M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $474K sold.
- 27 institutional investors held Theriva Biologics (TOVX) as of Q1 2021, up from 17 in Q4 2020.
- Funds reported $5.8M of Theriva Biologics stock for Q1 2021, up 722% quarter-over-quarter.
- 14 funds opened new Theriva Biologics positions in Q1 2021 and 4 closed out, a net change of +10 holders.
- The largest Theriva Biologics buyer in Q1 2021 was BlackRock, an estimated $1.83M added.
- The largest Theriva Biologics seller in Q1 2021 was Renaissance Technologies, an estimated $474K sold.
Based on aggregated 13F filings for Q1 2021.